Celltrion is making significant strides in the Japanese market with the recent launch of its intravenous formulation of SteQeyma, aimed at treating autoimmune diseases. This launch, which took place shortly after receiving regulatory approval from Japan’s Ministry of Health, Labour and Welfare in April, marks an important milestone for the company.
Expanding Treatment Options
The introduction of SteQeyma IV broadens its therapeutic applications beyond psoriasis and psoriatic arthritis to now include Crohn’s disease. This expansion is a strategic move to enhance the product’s appeal and increase its patient base, aligning with Celltrion’s goal of addressing various autoimmune conditions.
Leveraging Sales Expertise
Celltrion’s Japanese subsidiary intends to capitalize on its extensive experience in the market, drawing from its successful portfolio that includes notable products like Remsima and Yuflyma. By utilizing established sales channels and relationships with healthcare professionals, the company aims to accelerate SteQeyma’s adoption in Japan.
Building on Market Success
As of May, Remsima and Yuflyma commanded substantial portions of the Japanese biosimilar market, holding 46.9% and 19.5% shares, respectively. This strong foundation provides Celltrion with a competitive edge, allowing SteQeyma to benefit from existing market familiarity and brand recognition.
Strategic Marketing Initiatives
To further enhance its market presence, Celltrion plans to engage with key opinion leaders, particularly gastroenterologists and pharmacists. By fostering these relationships, the company hopes to encourage the prescription of SteQeyma, effectively increasing its footprint in the autoimmune treatment landscape.
Dual Formulation Advantage
SteQeyma stands out as the only ustekinumab biosimilar in Japan offering both intravenous and subcutaneous formulations. This flexibility allows healthcare providers to tailor treatments according to individual patient needs, starting with IV administration during the induction phase and transitioning to the SC formulation for maintenance therapy. Such versatility is expected to facilitate broader acceptance among patients and physicians alike.
Upcoming Medical Conferences
In an effort to promote SteQeyma and deepen connections within the medical community, Celltrion plans to participate in prominent medical conferences later this year, including the Japan Digestive Disease Week and the Japanese Society for Inflammatory Bowel Disease. These events will serve as platforms for educating healthcare professionals about the benefits of SteQeyma and enhancing its visibility in the market.
Preparing for Future Launches
Looking ahead, Celltrion is also gearing up for the launch of Remsima SC in Japan next year. By strengthening its network of doctors and pharmacists before this release, the company aims to bolster its reputation among healthcare professionals, ultimately impacting the preference for its products.
Conclusion
Celltrion’s launch of SteQeyma IV in Japan represents a strategic expansion into the autoimmune disease market, leveraging its established reputation and expertise. By introducing versatile treatment options and engaging with the medical community, Celltrion is well-positioned to enhance its presence and impact in Japan’s healthcare landscape.
- Key Takeaways:
- SteQeyma IV expands treatment options for autoimmune diseases.
- Celltrion utilizes existing market expertise to drive adoption.
- The dual formulation of SteQeyma offers tailored treatment for patients.
- Participation in medical conferences will enhance awareness and adoption.
- A strong network with healthcare professionals is crucial for future launches.
Read more → www.koreaherald.com